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Red Blood Cell Contamination of the
Final Cell Product Impairs the Efficacy of
Autologous Bone Marrow Mononuclear Cell Therapy
Birgit Assmus, MD,* Torsten Tonn, MD,‡ Florian H. Seeger, MD,*† Chang-Hwan Yoon, MD,†
David Leistner, MD,* Jens Klotsche, MSC,§ Volker Schächinger, MD,* Erhard Seifried, MD,‡
Andreas M. Zeiher, MD,* Stefanie Dimmeler, PHD†
Frankfurt and Dresden, Germany
Objectives The aim of this study was to identify an association between the quality and functional activity of bone marrow-
derived progenitor cells (BMCs) used for cardiovascular regenerative therapies and contractile recovery in pa-
tients with acute myocardial infarction included in the placebo-controlled REPAIR-AMI (Reinfusion of Enriched
Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial.
Background Isolation procedures of autologous BMCs might affect cell functionality and therapeutic efficacy.
Methods Quality of cell isolation was assessed by measuring the total number of isolated BMCs, CD34 and CD133
cells, their colony-forming unit (CFU) and invasion capacity, cell viability, and contamination of the final BMC
preparation with thrombocytes and red blood cells (RBCs).
Results The number of RBCs contaminating the final cell product significantly correlated with reduced recovery of left ventric-
ular ejection fraction 4 months after BMC therapy (p  0.007). Higher numbers of RBCs in the BMC preparation were
associated with reduced BMC viability (r  0.23, p  0.001), CFU capacity (r  0.16, p  0.03), and invasion ca-
pacity (r  0.27, p  0.001). To assess a causal role for RBC contamination, we coincubated isolated BMCs with
RBCs for 24 h in vitro. The addition of RBCs dose-dependently abrogated migratory capacity (p  0.003) and reduced
CFU capacity (p  0.05) of isolated BMCs. Neovascularization capacity was significantly impaired after infusion of
BMCs contaminated with RBCs, compared with BMCs alone (p  0.05). Mechanistically, the addition of RBCs was
associated with a profound reduction in mitochondrial membrane potential of BMCs.
Conclusions Contaminating RBCs affects the functionality of isolated BMCs and determines the extent of left ventricular ejec-
tion fraction recovery after intracoronary BMC infusion in patients with acute myocardial infarction. These results
suggest a bioactivity response relationship very much like a dose–response relationship in drug trials. (Reinfu-
sion of Enriched Progenitor cells and Infarct Remodeling in Acute Myocardial Infarction [REPAIR-AMI];
NCT00279175) (J Am Coll Cardiol 2010;55:1385–94) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.059r
l
c
a
v
t
I
c
b
C
d
m
S
flthough reperfusion therapy has significantly improved
rognosis of patients with acute myocardial infarction
AMI), the development of post-infarction heart failure
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009, accepted October 14, 2009.emains a major challenge, particularly in patients with
arge AMIs (1,2). Numerous experimental and several
linical studies suggest that cell therapy might provide an
ttractive novel option to beneficially interfere with left
entricular (LV) remodeling processes, and thereby at-
enuate the development of post-infarction heart failure.
n experimental studies, infusion of various types of
ells—including circulating endothelial progenitor cells,
one marrow mononuclear progenitor cells (BMCs),
D34 cells, mesenchymal stem cells, adipose-tissue
erived cells, and cardiac stem cells—leads to improve-
ent of neovascularization and cardiac function (3– 6).
o far, most of the clinical trials used autologous BMCs
or cell therapy of AMI (7). In contrast to an allogeneic
herapy with an “off the shelf ” cell product, autologous
n
m
D
m
b
u
r
o
M
o
4
c
t
c
t
o
s
i
fi
B
M
S
S
r
c
v
i
w
p
p
a
a
4
c
a
l
c
i
T
c
W
p
f
o
s
p
(
i
i
v
f
i
h
p
(
F
t
t
G
d
W
L
t
p
a
L
g
t
s
l
l
I
t
l

e
(
w
(
e
X
o
o
p
I
p
M
1386 Assmus et al. JACC Vol. 55, No. 13, 2010
RBC Contamination Impairs Bone Marrow Cell Therapy March 30, 2010:1385–94cell therapy requires isolation of
cells from each individual pa-
tient, and thus the applied cell
composit ion and function
might vary individually. Indeed,
risk factors for atherosclerosis
such as diabetes and age were
shown to impair cell function-
ality (8 –11). Previous experi-
mental studies and clinical pilot
trials showed that a reduction
of functional activity of the in-
fused cells defined as impaired
migratory capacity was associ-
ated with reduced therapeutic ef-
fects (12,13). However, the im-
pact of the composition of the
cell product and the potential
effect of contaminating cells are
unclear.
Therefore, we determined whether total cell number, the
umber of selected subpopulations of progenitor cells as
easured by fluorescent-activated cell sorting (FACS, Becton
ickinson, Franklin Lakes, New Jersey), in vitro assays to
easure cell activity, or contamination of the cell preparation
y platelets or erythrocytes affects the recovery of left ventric-
lar ejection fraction (LVEF) in the multicenter, double-blind,
andomized, placebo-controlled REPAIR-AMI (Reinfusion
f Enriched Progenitor cells And Infarct Remodeling in Acute
yocardial Infarction) trial including 204 patients with AMI,
f whom 101 patients have been treated with BMCs. At
-month follow-up, BMC-treated patients showed signifi-
antly improved LVEF compared with the placebo group, and
he treatment was associated with a reduced number of
omposite clinical end points at 1 year (14,15). Here we report
hat, among the various parameters tested, the contamination
f the isolated BMCs with red blood cells (RBCs) was a
ignificant independent predictor of reduced recovery of LVEF
n the BMC group. Experimental studies confirmed these
ndings by demonstrating that the addition of RBCs impairs
MC cell function in vitro and in vivo.
ethods
tudy population and protocol. Patients with an acute
T-segment elevation myocardial infarction successfully
eperfused with stent implantation with a residual signifi-
ant LV regional wall motion abnormality (LVEF45% by
isual estimate at the time of reperfusion therapy) were
ncluded in the REPAIR-AMI trial. A total of 204 patients
ere randomized to receive either intracoronary infusion of
lacebo medium or BMCs. In 187 patients (92 in the
lacebo and 95 in the BMC group), paired analysis of LV
ngiograms at baseline immediately before BMC/placebo
dministration (4.3  1 day after AMI reperfusion) and
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMC  bone marrow
mononuclear progenitor cell
CFU  colony-forming unit
FACS  fluorescent-
activated cell sorting
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NO  nitric oxide
RBC  red blood cell
(erythrocyte)
SDF  stromal cell-
derived factor-month follow-up were available (for detailed baseline wharacteristics see Schächinger et al. [14]). Cell processing
nd quality controls were performed in a central core
aboratory, and patients were randomized to receive intra-
oronary infusion of placebo medium or BMCs into the
nfarct-related artery during low-pressure balloon occlusion.
he BMCs were infused 17  11 h after bone marrow
ollection and were stored in X-vivo 10 medium (Lonza,
alkersville, Maryland)  20% autologous serum. In the
lacebo group, bone marrow was aspirated, processed, and
unctionally tested as in the BMC group, but patients received
nly X-Vivo 10 medium supplemented with 20% autologous
erum, never having contained any cells. Further details of cell
reparation and administration have been described previously
16,17). The ethics review board of each individual participat-
ng center approved the protocol, and the study was conducted
n accordance with the Declaration of Helsinki.
The BMCs for the experimental in vitro and in vivo
alidation and confirmation experiments were obtained
rom patients with ischemic cardiomyopathy undergoing
ntracoronary infusion of BMCs within an ongoing registry,
aving the same inclusion and exclusion criteria as the
reviously published randomized TOPCARE-CHD
Transplantation of Progenitor Cells and Recovery of LV
unction in Patients with Chronic Ischemic Heart Disease)
rial (18,19). The Ethics Review Board of the Hospital of
he Johann Wolfgang Goethe University of Frankfurt,
ermany, approved the protocol, and the study was con-
ucted in accordance with the Declaration of Helsinki.
ritten informed consent was obtained from each patient.
V angiography. Left ventricular angiograms were ob-
ained in identical standard projections at the baseline
rocedure (immediately before intracoronary cell infusion)
nd at 4-month follow-up. Quantitative analysis of paired
V angiograms was performed by an experienced investi-
ator (BA) in a central core laboratory, blinded to the
reatment modality of the individual patients with the
oftware CMS version 6.0 (Medis, Leiden, the Nether-
ands), as previously described (14). The LVEF was calcu-
ated with use of the area-length method.
solation of BMCs and viability assessment. Briefly, in
he REPAIR-AMI trial, bone marrow aspirates were di-
uted with 0.9% sodium chloride (1:5) and filtrated (100
m), and mononuclear cells were isolated by density gradi-
nt centrifugation with Lymphocyte Separation Medium
Lonza, 800 g, 20 min, without brake). Mononuclear cells
ere washed 3 times with 50 ml phosphate-buffered saline
800 g) and counted; viability was assessed by a dye
xclusion stain with trypan blue. Cells were resuspended in
-vivo 10 medium (Lonza), supplemented with 20% autol-
gous serum, and released for immediate use. Trial centers
utside of the greater area of Frankfurt received the cell
reparations the next day.
solation of erythrocytes (RBCs). With a leukocyte de-
letion filter for whole blood donations (Leucoflex LCR5,
acopharma, Langen, Germany), erythrocytes were elutedith 10 ml X-vivo 10 medium (Cambrex) from 5-ml bone
m
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March 30, 2010:1385–94 RBC Contamination Impairs Bone Marrow Cell Therapyarrow aspirate obtained from patients with ischemic heart
ailure. Enumeration of RBCs and the depleted total nu-
leated cells was performed with an automated differential
lood count (Sysmex XT 1800i [Sysmex, Mundelein, Illi-
ois], linearity of analysis: total nucleated cells: 0 to 100.0
03/l  300; RBC: 0 to 8.00  106/l  30.000; HCT:
.0% to 60  1%).
For all coincubation experiments, the defined amount of
BCs was added to the bone marrow preparation in X-vivo
0 medium containing 20% autologous serum and was
tored for 24 h at room temperature to mimic the settings
sed in the REPAIR-AMI trial (16). The RBCs and
MCs used were from the same patient.
low cytometry analysis of BMCs. After Ficoll density
radient centrifugation, BMCs were analyzed by FACS.
or the enumeration of bone marrow cell populations, we
sed directly conjugated antibodies against human CD45
FITC-labeled, BD Pharmingen, San Diego, California),
D34 (PE-labeled, BD Pharmingen), CD133 (APC-
abeled, Miltenyi, Bergisch Gladbach, Germany), and KDR
PE-labeled, R&D Systems, Minneapolis, Minnesota).
ating was performed according to the International Society
f Hematotherapy and Graft Engineering guideline (20).
For analysis of the mitochondrial membrane potential, BMCs
ere stained with the lipophilic cation 5,5=,6,6=tetrachloro-
,1=,3,3=-tetraethylbenzimidazol-carbocyanine iodide (JC-1, In-
itrogen, Carlsbad, California) according to the manufacturer’s
nstruction. Briefly, 24 h after storage, JC-1 was added to the cells
nd incubated for 20 min at 37°C. After washing with phosphate-
uffered saline, FACS analysis was immediately performed
FACS Canto II, Becton Dickinson).
ssessment of hematopoietic colonies. The BMCs (1 
05/dish) were seeded in methylcellulose plates (Methocult
F H4534, StemCell, Vancouver, British Columbia, Can-
da). Plates were studied under phase-contrast microscopy,
nd colony-forming units (CFUs) (colonies 50 cells) were
ounted after 14 days of incubation at 37°C by an indepen-
ent investigator. CFUs were examined in duplicates.
ssessment of invasion capacity of BMCs. A total of 1
06 BMCs were resuspended in 250 l X-vivo 10 medium
nd placed in the upper chamber of a modified Boyden
hamber filled with Matrigel (BioCoat invasion assay, 8 m
ore size, Becton Dickinson). Then, the chamber was
laced in a 24-well culture dish containing 500 l endothe-
ial basal medium. For stimulation of invasion, 100 ng/ml
tromal cell-derived factor (SDF)-1 was added in the lower
hamber. After incubation for 24 h at 37°C, transmigrated
ells were counted by independent investigators. Invasion
ssays were run in duplicates.
ell-matrix adhesion. Cell-matrix adhesion was per-
ormed as previously described (21). Ninety-six-well plates
ere coated overnight at 4°C with 2.5 g/ml soluble
ecombinant human ICAM-1 (R&D Systems) in coating
uffer (150 mmol/l sodium chloride, 20 mmol/l Tris hydro-
hloride, 1 mmol/l magnesium chloride, pH 9.0) and then
locked for 1 h at room temperature with 3% (w/v) veat-inactivated (2 h, 56°C) bovine serum albumin (Sigma,
t. Louis, Missouri). Human BMCs were stained with
=,7=-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein-
ctoxymethyl-ester (BCECF, Invitrogen; 2.5 M) and
tored overnight with different concentrations of RBCs as
ndicated in X-vivo medium containing 20% serum. Then,
ells were seeded at 1.1  105 cells/well in 100 l in the
oated wells for 10 min at 37°C. After washing with warm
PMI 1640, adherent cells were quantified in triplicates
ith a fluorescence plate reader (Synergy HT, Biotek, Bad
riedrichshall, Germany).
indlimb ischemia model. The neovascularization capac-
ty of the BMC was investigated in a murine model of
indlimb ischemia by use of 8-week-old athymic Balb/C
ude mice (Jackson Laboratory, Bar Harbor, Maine) weigh-
ng 18 to 22 g. The proximal portion of the femoral artery
ncluding the superficial and the deep branch as well as the
roximal portion of the saphenous artery were obliterated and
emoved with an electrical coagulator. The overlying skin was
losed with 7-0 silk suture. After 24 h, 1  106 BMC/mouse
ontaining the indicated number of RBCs were injected
ntravenously. Injection of 5  106 RBCs obtained after
eukocyte depletion of the bone marrow served as control.
imb perfusion measurements. After 21 days, we mea-
ured ischemic (right)/normal (left) limb perfusion ratio
ith a laser Doppler blood flowmeter (Laser Doppler
erfusion Imager System, moorLDI-Mark 2, Moor Instru-
ents, Wilmington, Delaware). The perfusions of the
schemic and nonischemic limb were calculated from mean
alue multiplied by the number of pixels of the region below
he inguinal ligament. To minimize variables including
mbient light and temperature, calculated perfusion was
xpressed as the ratio of ischemic to nonischemic hind-
imb perfusion.
tatistical analysis. If not stated otherwise, data are shown
s mean  SEM. Statistical comparisons were made by the
onparametric Wilcoxon 2-sample or Friedman=s tests
paired analyses) and the nonparametric Mann-Whitney U
r Kruskal-Wallis tests for between-group analyses. For
nivariate analysis, nonparametric Spearman correlation was
pplied. The multivariable analysis was done by a parametric
inear regression model. Because this approach assumes the
ormality of the dependent variable, we applied the Box-
ox transformation for the dependent variable in the
ultivariate analysis (22). The stepwise linear regression
odel was performed with the transformed approximately
ormal distributed dependent variable. Statistical signifi-
ance was assumed, if p  0.05. All reported p values are
-sided. All statistical analysis was performed with SPSS
version 17.0, SPSS, Inc., Chicago, Illinois).
esults
mpact of cell characteristics on functional recovery of
atients treated with BMCs. To analyze the effect of
arious cell quality and functional parameters on LV con-
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RBC Contamination Impairs Bone Marrow Cell Therapy March 30, 2010:1385–94ractile recovery measured as absolute change in LVEF, we
erformed a univariate analysis (Table 1). None of the cell
haracteristics, which include the total number of cells and
he subpopulations of hematopoietic progenitor cells, cor-
elated with the contractile recovery in the BMC-treated
atients. Because in the placebo group BMCs were isolated
ccordingly but were not infused in the patients, analysis of
he placebo group offered the unique opportunity to exclude
he possibility that the contamination of the final cell
roduct with RBCs is affected by patient-specific factors
nfluencing LVEF recovery.
Moreover, we quantified the cell intrinsic function of
rogenitor cells by measuring the hematopoietic CFU
apacity. Likewise, we determined both the basal as well as
DF-1–induced migratory capacity of BMCs, which was
hown to correlate with cell recruitment and homing after
aseline Cell Characteristics of the Final Cellreparation and Impact on Contractile Recoveryithin the REPA R-AMI Tr al
Table 1
Baseline Cell Charact ristics of the Final Cell
Preparation and Impact on Contractile Recovery
Within the REPAIR-AMI Trial
Median (25th/75th Percentile)
Placebo Patients
(n  103)
BMC Patients
(n  101)
Total mononuclear cells
isolated (106)
210 (110/336) 198 (130/284)
Viability (%) 99 (98/99) 99 (98/99)
Invasion basal 82 (49/125) 81 (46/139)
SDF-1–induced invasion 161 (90/210) 163 (98/209)
CFU capacity 29 (20/43) 27 (19/40)
CD34 CD45 (%) 1.43 (1.01/2.04) 1.35 (0.96/1.91)
CD133 CD45 (%) 1.10 (0.80/1.50) 1.00 (0.69/1.40)
CD45 KDR (%) 0.06 (0.30/0.80) 0.06 (0.03/0.11)
RBC (109) 0.30 (0.10/0.40) 0.20 (0.10/0.30)
Hematocrit (%) 0.3 (0.2/0.5) 0.2 (0.2/0.4)
Platelets (106) 150 (100/330) 140 (100/200)
Neutrophils (%) 38 (32/47) 36 (27/49)
Lymphocytic cells (%) 43 (36/50) 42 (34/53)
Univariate Analysis for LVEF
Placebo (n  92) BMC (n  95)
Total mononuclear cells
isolated (106)
r  0.05; p  0.7 r  0.08; p  0.5
Viability (%) r  0.17; p  0.1 r  0.15; p  0.2
Invasion basal r  0.07; p  0.5 r  0.05; p  0.6
SDF-1–induced invasion r  0.06; p  0.6 r  0.02; p  0.8
CFU capacity r  0.01; p  1.0 r  0.09; p  0.4
CD34 CD45 (%) r  0.09; p  0.4 r  0.10; p  0.3
CD133 CD45 (%) r  0.09, p  0.4 r  0.09, p  0.4
CD45 KDR (%) r  0.15, p  0.2 r  0.04, p  0.7
RBC (109) r  0.13, p  0.2 r  0.25, p  0.02
Hematocrit (%) r  0.10, p  0.3 r  0.22, p  0.04
Platelets (106) r  0.02, p  0.8 r  0.23, p  0.03
Neutrophils (%) r  0.12, p  0.3 r  0.06, p  0.6
Lymphocytic cells (%) r  0.03, p  0.7 r  0.10, p  0.4
ell characteristics of the placebo group are shown for comparative reasons only; these patients
id not receive the cell preparation but a cell-free placebo preparation.
BMC  bone marrow mononuclear progenitor cell; CFU  colony-forming unit; LVEF  left
entricular ejection fraction; RBC  red blood cell; REPAIR-AMI  Reinfusion of Enriched Progen-
tor Cells and Infarct Remodeling in Acute Myocardial Infarction; SDF stromal cell-derived factor.ntravascular administration of BMCs (13). However, none
Sf these functional properties of the administered BMCs
as associated with the extent of LV contractile recovery as
easured by changes in LVEF (Table 1). Only the number
f contaminating RBCs and the hematocrit of the final cell
roduct were significantly and inversely correlated with the
ecovery of LVEF, whereas no significant association was
etected for the number of contaminating neutrophils and
ymphocytic cells. In addition, the number of contaminating
latelets also showed a significant inverse correlation with
VEF recovery by univariate analysis (Table 1). To identify
hether RBC contamination is an independent predictor of
VEF recovery at 4 months, we performed a multivariate
nalysis including classical determinants of LV contractile
ecovery after AMI, like end-systolic volume, peak creati-
ine kinase levels, time of symptom onset to treatment, age,
nd the presence of diabetes as well as the previously
dentified predictors of LVEF recovery, namely a reduced
VEF at baseline and the time to treatment (14). As shown
n Table 2, the number of contaminating RBCs together
ith a reduced baseline LVEF and maximum creatinine
inase levels remained as the only independent predictors
or the recovery of LVEF. In contrast, the contaminating
latelets were not an independent predictor of LVEF
ecovery (Online Tables 1A and 1B). Thus, univariate
nd multivariate analysis revealed that the contamination
f the final cell product with RBCs is an independent
redictor of reduced recovery of LVEF in BMC-treated
atients with AMI. Of note, the negative impact of
BCs on the recovery of LVEF was only detected in the
MC group but not in the placebo control group, which
id not receive the cell product (Fig. 1A). Thus, the
mpact of RBC contamination is confined to patients
eceiving BMC administration but does not reflect a
atient-intrinsic association. Moreover, the number of
BCs in the bone marrow aspirate (before density
radient centrifugation) did not correlate with the recov-
ry of LVEF in the BMC group (p  0.73), indicating
hat the composition of the bone marrow aspirate before
rocessing did not affect functional recovery. These data
uggest that the number of contaminating RBCs in the
ultivariate Analysis for LVEFmprovement After 4 Months in the BMC GroupTable 2 Multivariate Analysis for LVEFImprovement After 4 Months in the BMC Group
p Value
Standardized
Coefficient
Age 0.57 0.06
Diabetes 0.22 0.13
Maximum creatinine kinase levels 0.02 0.27
Time symptom to stent 0.22 0.13
Baseline end-systolic volume 0.39 0.12
Baseline LVEF 0.001 0.48
Time to BMC administration 0.76 0.03
RBC (109) contamination of the final cell product 0.01 0.27ignificance (analysis of variance)  0.003.
Abbreviations as in Table 1.
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March 30, 2010:1385–94 RBC Contamination Impairs Bone Marrow Cell Therapyurified BMC population might have influenced the
unctionality of the cells used for cell therapy.
Therefore, in the next step, we analyzed the effect of RBC
ontamination on functional parameters of isolated BMCs
n the REPAIR-AMI trial. Importantly, increasing num-
ers of contaminating RBCs were not only associated with
reduced viability of the isolated cells, as measured by
rypan blue exclusion assay, but also correlated with a
ignificant impairment of invasion capacity and CFU ca-
acity of the isolated BMCs (Table 3, Fig. 1B), indicating
hat RBCs directly affect cell viability and cell functionality.
BC contamination impairs BMC function in vitro and
n vivo. To prospectively test the hypothesis that contamina-
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shows quartiles of RBC contamination. Statistical comparison between groups wa
viability within the REPAIR-AMI trial. Statistical comparison between groups was peion with RBCs influences the functionality of BMCs used for vell therapy, we coincubated isolated BMCs with increasing
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n the experiments reflects the median concentration of con-
aminating RBCs observed in the clinical trial. The RBCs
ose-dependently reduced the viability of BMCs (Fig. 2A),
onsistent with the statistical evaluation of the clinical trial.
urthermore, the invasion capacity of BMCs at baseline and
fter stimulation with SDF-1 was significantly reduced by
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RBC Contamination Impairs Bone Marrow Cell Therapy March 30, 2010:1385–94BCs for 24 h further reduced the formation of
ranulocyte/macrophage-CFUs, a prototypical marker for
unctionally competent hematopoietic progenitor cells (Fig.
C), but did not affect the adhesion of the BMCs (Fig. 2D).
The integrity and function of mitochondria is essential
or stem cell competence (23), the migration of progenitor
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nfluence of RBC Contamination on Cellharact ristics Within the REPAIR-AMI TrialTable 3 Influence of RBC Contamination on CellCharacteristics Within the REPAIR-AMI Trial
Univariate Analysis (RBC/MNC)
Viability (%) r0.23; p 0.001
Invasion basal r0.21; p 0.003
SDF-1–induced invasion r0.27; p 0.001
CFU capacity r0.16; p 0.03
CD34 CD45 (%) r 0.13; p 0.06
CD133 CD45 (%) r0.04, p 0.5
CD45 KDR (%) r0.06, p 0.4
NC  mononuclear cell; other abbreviations as in Table 1.ells (24), and cell survival (25). Therefore, we tested
hether the addition of RBCs might influence mitochon-
rial function of BMCs by measuring the mitochondrial
embrane potential with JC-1 staining. As demonstrated in
igure 3, contamination with RBCs dose-dependently re-
uced the quantitative mitochondrial membrane potential
f BMCs, indicating that RBCs impair the mitochondrial
unction of BMCs.
To test whether RBCs affect the functional benefit of cell
herapy in vivo, we injected BMCs that had been co-
ncubated with or without RBCs for 24 h into nude mice
fter induction of hindlimb ischemia. Indeed, laser Doppler-
erived blood flow recovery was significantly higher in mice
reated with BMCs compared with the group that received
MCs after co-incubation with RBCs (Fig. 4). Taken to-
ether, these data confirm that RBC contamination dose-
ependently impairs the in vitro and in vivo functions of
solated bone marrow-derived mononuclear cells.
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March 30, 2010:1385–94 RBC Contamination Impairs Bone Marrow Cell TherapyBCs impair BMC function via a secreted factor. Fi-
ally, we performed further experiments to gain mechanistic
nsights into RBC action on BMC function. Because
emolysis of RBCs is well-known to result in high levels of
ree heme, causing cellular injury (26), we tested the
ypothesis of whether the release of hemoglobin might
ause BMC dysfunction. However, supernatants of RBCs
fter hypotonic lysis did not affect BMC invasion (Fig. 5A)
ndicating that the release of hemoglobin by RBCs is
nlikely to induce migratory defects of BMCs. Next, we
ested whether a secreted RBC-derived factor is sufficient to
mpair BMCs. Therefore, RBCs were incubated in X-vivo
edium for 24 h, and the supernatant was subsequently
ncubated with BMCs. As shown in Figure 5B, superna-
ants of intact RBCs indeed inhibited SDF-1–induced
nvasion of BMCs. Furthermore, we addressed whether the
ffect might be caused by shed microparticles and, therefore,
entrifuged the RBC supernatant to pellet microparticles.
owever, RBC-derived microparticles did not affect BMC
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ependently impair BMC functions involved in functional
ecovery after ischemia.
It is well-established that risk factors for coronary artery
isease impair the functionality of patient-derived BMCs
ith respect to their capacity to induce neovascularization
A
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Figure 4 Impairment of In Vivo Functions of BMCs
Representative pictures (A) and quantitative analysis (B) of relative perfusion in a
BMCs stored 24 h according to the indicated conditions. Data are mean  SD of
Figure 5 Mechanistic Insights Into the BMC Impairment Media
(A) RBCs (5  106 RBC/1  106 BMC) were pelleted and lysed with 50 l of wat
fuged for 10 min at 800 g. The resulting supernatants or the pellet (resolved in 40
invasion was determined by using a modified Boyden chamber assay. Data are me
(B) RBCs were incubated in X-vivo-10 medium for 24 h at room temperature, and the
20,500 g for 45 min. After centrifugation, the supernatant or the resolved pellet was
assays with SDF-1 as stimulus. Data are mean  SEM of n  2 experiments measur9). Moreover, previous clinical pilot trials suggested that
he measurement of cell functionality by detecting the
nvasive and migrating capacity defines the benefit of cell
herapy (12,18). Whereas these parameters did not seem to
e significant univariate determinants in the present study in
atients with AMI, the invasive capacity in response to the
BMC
BMC+RBC
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mb ischemia model 21 days after injection of RBCs or
mice. p  0.05 versus BMCs alone. Abbreviations as in Figure 1.
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uplicates. p  0.05 versus control. Abbreviations as in Figures 1 and 2.R
el
at
iv
e
 p
er
fu
si
on
 (%
lef
t l
im
b) 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
R
el
at
iv
e
 p
er
fu
si
on
 (%
lef
t l
im
b) 
hindli
n  8ted b
er for
0 l m
an  S
conditi
added
ed in d
p
i
v
S
v
r
i
B
p
b
t
d
c
i
c
n
M
c
n
B
R
B
i
c
w
l
a
r
m
t
h
s
t
m
a
h
m
A
a
e
m
p
t
m
i
f
h
i
o
m
i
t
b
c
m
R
f
i
(
w
i
m
e
r
m
f
c
c
v
T
a
u
t
q
A
T
s
B
Z
a
a
c
R
(
T
z
R
1393JACC Vol. 55, No. 13, 2010 Assmus et al.
March 30, 2010:1385–94 RBC Contamination Impairs Bone Marrow Cell Therapyhysiologically important cytokine SDF-1 (27) was signif-
cantly associated with improved LVEF recovery in multi-
ariate statistical analysis. Importantly, normalization of
DF-1–induced invasion by the contaminating RBCs pro-
ided a highly significant predictor of global LV contractile
ecovery (Online Table 2, Online Fig. 1). Thus, combining
ntrinsic patient-determined functional parameters of
MCs with extrinsic effects imposed by the cell isolation
rocedure indeed discloses a cause-and-effect relationship
etween the cell product and LVEF recovery after cell
herapy in patients with AMI.
Interestingly, in the REPAIR-AMI trial, we could not
etect an association between the applied cell numbers and
ontractile recovery. This might be because 85% of the patients
n the BMC group received BMC numbers exceeding 108
ells, which was identified as the minimum cell number
ecessary for beneficial effects in a recent meta-analysis by
artin-Rendon et al. (28). Thus, to detect a potential direct
ell number-related dose–response relationship, it seems to be
ecessary to prospectively administer predefined numbers of
MCs varying at least by a factor of 100-fold difference.
Mechanistically, our results suggest that addition of
BCs affects the mitochondrial membrane potential of
MCs. Mitochondria act as important signaling organelles
n endothelial cells (29) and are required for the migratory
apacity of endothelial progenitor cells (22). Moreover, it is
ell-established that mitochondrial function and metabo-
ism are important determinants of stem cell self-renewal
nd differentiation (30,31). The mitochondrial marker dye
hodamine 123, which measures mitochondrial activity and
embrane polarity, shows an age-related relationship be-
ween the mitochondrial dye efflux and the ability of human
ematopoietic stem cells to repopulate the hematopoietic
ystem of irradiated animals (32,33). Importantly, adminis-
ration of progenitor cells with a reduced mitochondrial
embrane potential induced by hypoxia was associated with
significantly impaired neovascularization capacity in the
indlimb ischemia model (34). By contrast, increasing the
itochondrial membrane potential of progenitor cells via an
MP-activated protein kinase-dependent mechanism was
ssociated with enhanced migration and functional re-
ndothelialization (24). Thus, the functional integrity of the
itochondria seems to be essential not only for stem and
rogenitor cell function and survival but also for regulating
he vascular repair capacity of administered cells.
The question remains: by which signaling mechanism
ight RBCs affect viability and mitochondrial function of
solated BMCs? Hemolysis of RBCs results in high levels of
ree heme causing cellular injury (26). Moreover, free
emoglobin was shown not only to directly induce apoptosis
n cultured endothelial cells (35) but also to scavenge nitric
xide (NO). Nitric oxide plays a crucial role for stem cell
aintenance, differentiation, and neovascularization capac-
ty (36–39) and increases mitochondrial function in endo-
helial cells (29), thus raising the hypothesis that reduced
ioactive NO levels in the BMC suspension might haveontributed to impaired benefit of BMCs associated with
itochondrial dysfunction. However, supernatants of lysed
BCs containing free hemoglobin did not affect BMC
unctions, and the addition of NO donors did not rescue the
mpaired migratory capacity of BMCs induced by RBCs
data not shown). In contrast, supernatants of intact RBCs
ere shown to significantly reduce BMC invasion, indicat-
ng that an actively secreted factor mediates BMC impair-
ent. Further subfractionation of these RBC supernatants
xcluded a role of microparticles. On the basis of these
esults, one might speculate that secreted lipids or proteins
ight mediate the effects of RBCs on BMCs.
In summary, the results of the present study demonstrate
or the first time an association between cell quality and
ontractile recovery within a large randomized, multicenter
linical trial, suggesting a bioactivity response relationship
ery much like a dose–response relationship in drug trials.
herefore, future studies are warranted to establish rapid
nd reliable tests for quality control of the cell product when
sing autologous BMCs. On the basis of the presented data,
esting for contaminating RBCs might be used as an ad hoc
uality control parameter for future clinical trials.
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